Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4844-4852

  Henry Jr , Kenneth J ^a,b   Wasicak, James ^a   Tasker, Andrew S ^a   Cohen, Jerome ^a   Ewing, Patricia ^a   Mitten, Michael ^a   Larsen, John J ^a   Kalvin, Douglas M ^a   Swenson, Rolf ^a   Ng, Shi Chung ^a   Saeed, Badr ^a   Cherian, Sajeev ^a   Sham, Hing ^a   Rosenberg, Saul H ^a  

^a ABBOTT LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRENYLATION; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; METHIONINE; MICE; MICE, NUDE; MOLECULAR MIMICRY; NEOPLASM TRANSPLANTATION; PEPTIDES; PROTEIN ISOPRENYLATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0344822640     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990335v     Document Type: Article

References (53)

1. Barbacid, M. ras Genes. Annu. Rev. Biochem. 1987, 56, 779-827.
2. (a) Bos, J. L. ras Oncogenes in Human Cancer: A Review. Cancer Res. 1989, 49, 4682-4689.
3. (b) Kiaris, H.; Spandidos, D. A. Mutations of ras genes in human tumours (Review). Int. J. Oncol. 1995, 7, 413-421.
4. ras in Carcinogenesis. Pathol. Res. Pract. 1996, 192, 658-668.
5. (d) Park, H.-W.; Beese, L. S. Protein Farnesyltransferase. Curr. Opin. Struct. Biol. 1997, 7, 873-880.
6. (a) Cuatrecasas, M.; Erill, N.; Musulen, E.; Costa, I.; Matias-Guiu, X.; Prat, J. K-ras Mutations in Nonmucinous Ovarian Epithelial Tumors. A Molecular Analysis and Clinicopathologic Study of 144 Patients. Cancer 1998, 82, 1088-1095.
7. (b) Cuatrecasas, M.; Villanueva, A.; Matias-Guiu, X.; Prat, J. K-ras Mutations in Mucinous Ovarian Tumors. A Clinicopathologic and Molecular Study of 95 Cases. Cancer 1997, 79, 1581-1586.
8. (c) Mandai, M.; Konishi, I.; Kuroda, H.; Komatsu, T.; Yamamoto, S.; Nanbu, K.; Matsushita, K.; Fukumoto, M.; Yamabe, H.; Mori, T. Heterogeneous Distribution of K-ras-mutated Epithelia in Mucinous Ovarian Tumors With Special Reference to Histopathology. Hum. Pathol. 1998, 29, 34-40.
9. Casey, P. J.; Solski, P. A.; Der, C. I.; Buss, J. E. p21 ras is Modified by a Farnesyl Isoprenoid Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8223.
10. Kato, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E.; Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity, Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6403-6407.
11. Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell Biol. 1992, 4, 1008-1016.
12. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
13. Newman, C. M.; Magee, A. I. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim. Biophys. Acta 1993, 1155, 79-96.
14. Schafer, W. R.; Rine, J. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 1992, 26, 209-237.
15. Recent reviews: (a) Gibbs, J. B.; Oliff, A. The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics. Annu. Rev. Pharmocol. Toxicol. 1997, 37, 143-166.
16. (b) Leonard, D. M. Ras Farnesyltransferase: A New Therapeutic Target. J. Med. Chem. 1997, 40, 2971-2990.
17. 2X-competitive inhibitors of farnesyltransferase as anticancer agents. Trends Pharmacol. Sci. 1997, 18, 437-444.
18. (d) Yang, W.; Del Villar, K.; Urano, J.; Mitsuzawa, H.; Tamanoi, F. Advances in the Development of Farnesyltransferase Inhibi-tors: Substrate Recognition by Protein Farnesyltransferase. J. Cell. Biol. Suppl. 1997, 27, 12-19.
19. (e) Sebti, S. M.; Hamilton, A. D. New Approaches to Anticancer Drug Design Based on the Inhibition of Farnesyltransferase. DDT 1998, 3, 26-33.
20. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. T.; McDowell, R. S.; Crowley, C.; Lucas, B.; Levinson, A.; Marsters, J. C. Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells. Science 1993, 260, 1937.
21. (a) Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; deSolms, S. J.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein Farnesyltransferase Inhibitors Block the Growth of Ras-Dependent Tumors in Nude Mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141.
22. (b) Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Hamilton, K.; Handt, L. K.; Hartman, G. D.; Koblan, K. S.; Kral, A. M.; Miller, P. J.; Mosser, S. D.; O'Neil, T. J.; Rands, F.; Schaber, M. D.; Gibbs, J. B.; Oliff, A, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1995, 1 (8), 792-797.
23. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deanna, A. A.; Garsky, V. M.; Scholtz, T. H.; Gibbs, J. B.; Smith, R. L. Pseudopeptide Inhibitors of Ras Farnseyl-protein Transferase. J. Med. Chem. 1994, 37, 725.
24. (a) deSolms, S. J.; Deana, A. A.; Giuliani, E. A.; Graham, S. L.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Scholtz, T. H.; Wiggins, J. M.; Gibbs, J. B.; Smith, R. L. Pseudopeptide Inhibitors of Protein Farnesyltransferase. J. Med. Chem. 1995, 38, 3967-3971.
25. (b) Anthony, N. J.; Gomez, R. P.; Schaber, M. D.; Mosser, S. D.; Hamilton, K. A.; O'Neil, T. J.; Koblan, K. S.; Graham, S. L.; Hartman, G. D.; Shah, D.; Rands, E.; Kohl, N. E.; Gibbs, J. B.; Oliff, A. I., Design and in Vivo Analysis of Potent Non-Thiol Inhibitiors of Farnesyl Protein Transferase. J. Med. Chem. 1999, 42, 3356-3368.
26. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
27. Leftheris, K; Kline, T.; Vite, G. D.; Cho, Y. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weller, H. N.; Andahazy, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity. J. Med. Chem. 1996, 39, 224-236.
28. Burns, C. J.; Guitton, J.-D.; Baudoin, B.; Lelievre, Y.; Duchesne, M.; Parker, F.; Fromage, N.; Commercon, A. Novel Conformationally Extended Naphthalene-Based Inhibitors of Farnesyltransferase. J. Med. Chem. 1997, 40, 1763-1767.
29. Njoroge, F. G.; Vibulbhan, B.; Rane, D. F.; Bishop, W. R.; Petrin, J.; Patton, R.; Bryant, M. S.; Chen, K.-J.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Structure-Activity Relationship of 3-Substituted N-(Pyridinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b] pyridin-11-ylidene)-piperidine Inhibitors of Farnesy-Protein Transferase: Design and Synthesis of in-Vivo Active Antitumor Compounds. J. Med. Chem. 1997, 40, 4290-4301.
30. deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Koblan, K. S.; Kohl, N. E.; Mosser, S. C.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Scholz, T. H.; Wiscount, C. M.; Gibbs, J. B.; Smith, R. L. N-Arylaalkyl Pseudopeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1998, 41, 2651-2656.
31. Mallams, A. K.; Rossman, R. R.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K.; Petrin, J.; Wang, L.; Patton, R.; Bishop, W. R.; Carr, D. M.; Kirschmeier, P.; Catino, J. J.; Bryant, M. S.; Chen, K.-J.; Korfmacher, W. A.; Nardo, C.; Wang, S.; Nomeir, A. A.; Lin, C.-C.; Li, Z. Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine and (1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. J. Med. Chem. 1998, 41, 877-893.
32. Njoroge, F. G.; Vibulbhan, B.; Pinto, P.; Bishop, W. R.; Bryant, M. S.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N-Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity. J. Med. Chem. 1998, 41, 1561-1567.
33. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. J. Biol. Chem. 1995, 270, 26802-26806.
34. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma With K-Ras Mutation and p53 Deletion. Cancer Res. 1895, 55, 4243-4247.
35. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors. J. Med. Chem. 1996, 39, 217-223.
36. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Both Farnesyltransferase and Geranylgeranyltransferase I Inihibitors are Required for Inhibition of Oncogenic K-Ras Prenylation but Each Alone is Sufficient to Suppress Human Tumor Growth in Nude Mouse Xenografts. Oncogene 1998, 16, 1467-1473.
37. (a) Augeri, D. J.; O'Connor, S. J.; Janowick, D.; Szczepankiewicz, B.; Sullivan, G.; Larsen, J.; Kalvin, D.; Cohen, J.; Devine, E.; Zhang, H.; Cherian, S.; Saeed, B.; Ng, S.-C.; Rosenberg, S. Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase. J. Med. Chem. 1998, 41, 4288-4300.
38. (b) Shen, W.; Fakhoury, S.; Donner, G.; Henry, K.; Lee, J.; Zhang, H.; Cohen, J.; Warner, R.; Saeed, B.; Cherian, S.; Tahir, S.; Kovar, P.; Bauch, J.; Ng, S.-C.; Marsh, K.; Sham, H.; Rosenberg, S. Potent Inhibitors of Protein Farnesyltransferase: Heteroarenes as Cysteine Replacements. Bioorg. Med. Chem. Lett. 1999, 9, 703-708.
39. (c) Augeri, D. J.; Janowick, D.; Kalvin, D.; Sullivan, G.; Larsen, J.; Dickman, D.; Ding, H.; Cohen, J.; Lee, J.; Warner, R.; Kovar, P.; Cherian, S.; Saeed, B.; Zhang, H.; Tahir, S.; Ng, S.-C.; Sham, H.; Rosenberg, S. H. Potent and Orally Bioavailable Noncycsteine-Containing Inhibitors of Portein Farnesyltransferase. Bioorg. Med. Chem. Lett. 1999, 9, 1069-1074.
40. (d) O'Connor, S. J.; Barr, K. J.; Wang, L.; Sorensen, B. K.; Tasker, A. S.; Sham, H.; Ng, S.-C.; Cohen, J.; Devine, E.; Cherian, S.; Saeed, B.; Zhang, H.; Lee, J. Y.; Warner, R.; Tahir, S.; Kovar, P.; Ewing, P.; Alder, J.; Mitten, M.; Leal, J.; Marsh, K.; Bauch, J.; Hoffman, D. J.; Sebti, S. M.; Rosenberg, S. H. Second-Generation Peptidomimetic Inhibitiors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy. J. Med. Chem. 1999, 42, 3701-3710.
41. (a) Lebowitz, P. F.; Davide, J. P.; Prendergast, G. C. Evidence that Farnesyltransferase Inhibitors Suppress Ras Transformation by Interfering with Rho Activity. Mol. Cell. Biol. 1995, 15, 6613-6622.
42. (b) Cox, A. D.; Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1997, 1333, F51-71.
43. (c) Clark, G. J.; Kinch, M. S.; Rogers-Graham, K.; Sebti, S. M.; Hamilton, A. D.; Der, C. J. The Ras-related Protein Rheb is Farnesylated and Antagonizes Ras Signaling and Transformation. J. Biol. Chem. 1997, 272, 10608-10615.
44. (d) Gibbs, J, B.; Graham, S. L.; Hartman, G. D.; Koblan, K. S.; Kohl, N. E.; Omer, C. A.; Oliff, A. Farnesyltransferase Inhibitors versus Ras Inhibitors. Curr. Opin. Chem. Biol. 1997, 1, 197-203.
45. Wang, S.-S. p-Alkoxybenzyl Alcohol Resin and p-alkoxybenzy-loxycarbonylhydrazide Resin for Solid-Phase Synthesis of Protected Peptide Fragments. J. Am. Chem. Soc. 1972, 95, 1328.
46. (a) Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
47. (b) Carpino, L. A.; El-Faham, A.; Minor, C. A.; Albericio, F. Advantageous Applications of Azabenzotriazole (Triazolopyridine)-based Coupling Reagents to Solid-phase Peptide Synthesis. J. Chem. Soc., Chem. Commun. 1994, 201-203.
48. Sarin, V. K.; Kent, S. B. H.; Tam, J. P.; Merrifield, R. B. Quantitative Monitoring of Solid-phase Peptide Synthesis by the Ninhydrin Reaction. Anal. Biochem. 1981, 117, 147-157.
49. Mancuso, A. J.; Huang, S.-L.; Swern, D. Oxidation of Long-Chain and Related Alcohols to Carbonyls by Dimethyl Sulfoxide "Activated" by Oxalyl Chloride. J. Org. Chem. 1978, 43, 2480.
50. (a) Ramanjulu, J. M.; Joullie, M. M. N-Alkylation of Amino Acid Esters Using Sodium Triacetoxyborohydride. Synth. Commun. 1996, 26, 1379-1384.
51. (b) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Naryanoff, C. A.; Shah, R. D. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures. J. Org. Chem. 1996, 61, 3849-3862.
52. Park, H.-W.; Boduluri, S. R.; Moomaw, J. F.; Casey, P. J.; Beese, L. S. Crystal Structure of Protein Farnesyltransferase at 2.25 Angstrom Resolution. Science 1997, 275, 1800-1804.
53. Henry, K. J. Unpublished results, Abbott Laboratories.